<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Goette, Andreas</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ARB Therapy in the Setting of Paroxysmal AF: Results from the ANTIPAF Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-16</style></pages><abstract><style  face="normal" font="default" size="100%">Olmesartan does not reduce the incidence of atrial fibrillation (AF) episodes among patients with paroxysmal AF without structural heart disease, according to findings from the Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation [ANTIPAF; NCT0098137] trial.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>